🇺🇸 alpha-glucosidase inhibitor in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Altered State Of Consciousness — 1 report (10%)
2. Blood Glucose Decreased — 1 report (10%)
3. Cerebral Infarction — 1 report (10%)
4. Constipation — 1 report (10%)
5. Diabetes Mellitus — 1 report (10%)
6. Diabetes Mellitus Inadequate Control — 1 report (10%)
7. Diabetic Ketoacidosis — 1 report (10%)
8. Glycosylated Haemoglobin Increased — 1 report (10%)
9. Insomnia — 1 report (10%)
10. Neurosis — 1 report (10%)

Source database →

Frequently asked questions

Is alpha-glucosidase inhibitor approved in United States?

alpha-glucosidase inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for alpha-glucosidase inhibitor in United States?

Tanabe Pharma Corporation is the originator. The local marketing authorisation holder may differ — check the official source linked above.